Erschienen in:
Journal of Antimicrobial Chemotherapy, 70 (2015) 4, Seite 1155-1160
Sprache:
Englisch
DOI:
10.1093/jac/dku519
ISSN:
1460-2091;
0305-7453
Entstehung:
Anmerkungen:
Beschreibung:
AbstractObjectivesThe equilibrative nucleoside transporter 1 (ENT1) is the main protein involved in ribavirin cellular uptake. Polymorphisms at the SLC29A1 gene, encoding ENT1, may influence ribavirin-associated anaemia, which is observed at a higher incidence with telaprevir in combination with pegylated-IFNα and ribavirin than with pegylated-IFNα and ribavirin alone. In this study, we investigated the role of the rs760370 SLC29A1 variant in ribavirin-induced anaemia in chronic hepatitis C patients treated with telaprevir-based triple therapy.MethodsForty patients infected with hepatitis C virus (HCV) genotype 1 and starting anti-HCV therapy with telaprevir in combination with pegylated-IFN/ribavirin were prospectively evaluated for SNPs at the SLC29A1 gene and inosine triphosphatase (ITPA) genes using a real-time PCR system.Results40% of patients developed severe anaemia with a haemoglobin (Hb) decline ≥5 g/dL from the pretreatment value. The SLC29A1 rs760370 GG genotype was associated with the severity of Hb decrease as expressed by the median (IQR) Hb nadir change from baseline [−5.4 (−5.6; −5.0) g/dL in GG versus −4.2 (−5.1; −3.4) in AA/AG genotype; P = 0.05] and by the Hb decrease ≥5 g/dL by week 12 (77.8% of GG carriers versus 24% of AA/AG; P < 0.01). In multivariate analysis, older age (P = 0.03), lower baseline Hb concentration (P = 0.02) and SLC29A1 rs760370 GG (P = 0.02) were associated with the development of severe anaemia during treatment, whereas no association was found with ITPA SNPs in our population receiving telaprevir-based therapy.ConclusionsIn patients with chronic hepatitis C receiving telaprevir-based therapy, SNP rs760370A>G at the SLC29A1 gene influences the severity of ribavirin-induced anaemia, possibly mirroring the erythrocyte uptake of ribavirin.